Linked Life Data

19027420

Source:http://linkedlifedata.com/resource/pubmed/id/19027420

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2008-11-25
pubmed:abstractText
To investigate long-term responsiveness of patients with severe uveitis associated with Behçet disease to interferon alpha2a (IFN-alpha2a).
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1879-1891
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
146
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
837-44.e1
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:19027420-Adolescent, pubmed-meshheading:19027420-Adult, pubmed-meshheading:19027420-Behcet Syndrome, pubmed-meshheading:19027420-Child, pubmed-meshheading:19027420-Drug Therapy, Combination, pubmed-meshheading:19027420-Female, pubmed-meshheading:19027420-Fluorescein Angiography, pubmed-meshheading:19027420-Follow-Up Studies, pubmed-meshheading:19027420-Humans, pubmed-meshheading:19027420-Immunosuppressive Agents, pubmed-meshheading:19027420-Infusions, Subcutaneous, pubmed-meshheading:19027420-Interferon-alpha, pubmed-meshheading:19027420-Male, pubmed-meshheading:19027420-Methylprednisolone, pubmed-meshheading:19027420-Middle Aged, pubmed-meshheading:19027420-Prednisone, pubmed-meshheading:19027420-Recombinant Proteins, pubmed-meshheading:19027420-Recurrence, pubmed-meshheading:19027420-Retrospective Studies, pubmed-meshheading:19027420-Treatment Outcome, pubmed-meshheading:19027420-Uveitis, pubmed-meshheading:19027420-Visual Acuity, pubmed-meshheading:19027420-Young Adult
pubmed:year
2008
pubmed:articleTitle
Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet disease.
pubmed:affiliation
Department of Ophthalmology, University of Paris VI, Pitié-Salpêtrière Hospital, Paris, France.
pubmed:publicationType
Journal Article